Literature DB >> 14687622

T cell receptor gamma (TCRG) gene rearrangements in Brazilian children with acute lymphoblastic leukemia: analysis and implications for the study of minimal residual disease.

Carlos A Scrideli1, Rosane G P Queiróz, Simone Kashima, Bianca O M Sankarankutty, Luiz G Tone.   

Abstract

The high frequency of T cell receptor gamma (TCRG) gene rearrangements in both B-lineage and T cell acute lymphoblastic leukemia (ALL), its easy detection and the lower incidence of oligoclonality make this gene one of the main target for the detection of minimal residual disease by PCR in childhood ALL. We analyzed the frequency and type of TCRG rearrangements in DNA samples obtained from the bone marrow of 102 Brazilian children at diagnosis using PCR and automatic sequencing. TCRG rearrangements were found in 69% of patients with B-lineage ALL and in 94% of patients with T cell ALL. In contrast to other studies, rearrangements involving the Vgamma9 segment reported to be uncommon were the most frequent both in B-lineage and T cell ALL and involved 49/109 (45%) of the rearranged alleles. This fact should be considered when standardizing consensus primers for the study of minimal residual disease in different populations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14687622     DOI: 10.1016/j.leukres.2003.07.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Comparative investigations of T cell receptor gamma gene rearrangements in frozen and formalin-fixed paraffin wax-embedded tissues by capillary electrophoresis.

Authors:  M Christensen; A D Funder; K Bendix; F B Soerensen
Journal:  J Clin Pathol       Date:  2006-02-06       Impact factor: 3.411

2.  Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.

Authors:  Małgorzata Dawidowska; Justyna Jółkowska; Tomasz Szczepański; Katarzyna Derwich; Jacek Wachowiak; Michał Witt
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-12-01       Impact factor: 4.291

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.